HealthcarePatient Communication & Language Access3MediumAdvanced Paramedic$ implied

Advanced paramedics lack a structured, evidence-based tool to guide conversations with patients and families about the realistic outcomes of CPR and its appropriateness for specific individuals.

No purpose-built digital tool exists to help paramedics structure conversations about CPR's effectiveness, leading to reliance on anecdotal stories and pressure from families to continue futile resuscitation.

47
0
Opp. Score
47
Severity
3Medium
Willingness to Pay
implied
Added
May 29, 2026
App Concept

ResusCompass

ResusCompass is a mobile-first clinical communication aid for paramedics to have informed, compassionate conversations about CPR outcomes. It provides personalized risk-benefit visualizations based on patient factors (age, comorbidities, frailty) using validated clinical data, and includes script prompts and shared decision-making guides. It replaces ad-hoc talking points with a standardized, evidence-based approach.

Key Features
  • Patient-specific CPR outcome calculator using validated scores (e.g., ROSC after NACA, frailty index)
  • Visual risk-benefit display (e.g., survival-to-discharge percentages with and without comorbidities)
  • Conversation script library aligned to different patient scenarios (e.g., frail elderly, terminal illness)
  • Documentation template to record shared decision and DNACPR discussion
  • Integration with electronic patient care records (ePCR) for seamless documentation
Target Users: Advanced paramedics, critical care paramedics, and emergency medical services physicians in pre-hospital settings, particularly in the UK NHS.
Revenue Model: £9.99/month per user subscription for paramedics; Enterprise licensing for ambulance trusts at £5-10 per clinician per month with volume discounts.
Part of App Idea
VoxCare Translator

Want to go deeper?

Sign up to save ideas, run AI analysis, and track opportunities in your personal workspace. Founding members get full access.

Join Beta

Solutions (0)

Discussion (0)

No comments yet

Join the beta — full access for the first 1,000 builders

Join Beta